Abstract: This invention relates to the treatment of a neuropsychiatric disorder, such as schizophrenia or Parkinson's disease, by administration (for example, transdermally) of tilivapram, zatolmilast, roflumilast, or a pharmaceutically acceptable salt thereof.

Abstract: A light fixture includes an array of light-emitting diode (“LED”) light sources, a driver circuit that drives the array of LED light sources, and a controller. Controlling the light fixture includes receiving a first output color spectrum for the array of LED light sources that corresponds to a fixture color output spectrum, performing an optical modification of the fixture output color spectrum, determining, based on the optical modification, a compensation value to modify the first output color spectrum to a second output color spectrum that compensates for changes to the fixture output color spectrum resulting from the optical modification, generating, based on the compensation value, a first control signal to drive the array of LED light sources at the second output color spectrum, and controlling the driver circuit using the first control signal.

Abstract: Embodiments generate a resilience analysis of a real-world system. One such embodiment constructs a network graph representing a real-world system for providing function(s) by generating node(s) corresponding to the function(s) and generating edge(s). Each of the edge(s) links a pair of the node(s) and represents a causal dependency between respective functions corresponding to the pair of the node(s). In turn, via a first model, based on the network graph, configuration(s) of the real-world system are simulated by modifying a configuration of a function corresponding to a node of the node(s) or a causal dependency corresponding to an edge of the edge(s). Then, via the first model, based on the simulating, a resilience analysis of the real-world system is generated.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of agomelatine (or a prodrug or salt thereof) in the treatment of major depressive disorder or bipolar disorder, including the selection of patients who would most benefit from agomelatine.

Abstract: This invention relates to the use of agomelatine (or a prodrug or salt thereof) in the treatment of major depressive disorder or bipolar disorder, including the selection of patients who would most benefit from agomelatine.

Abstract: This invention relates to the use of agomelatine (or a prodrug or salt thereof) in the treatment of major depressive disorder or bipolar disorder, including the selection of patients who would most benefit from agomelatine.

Abstract: This invention relates to the use of agomelatine (or a prodrug or salt thereof) in the treatment of major depressive disorder or bipolar disorder, including the selection of patients who would most benefit from agomelatine.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MIDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and/or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and/or memory or certain EEG characteristics.

Abstract: A light fixture includes an array of light-emitting diode (“LED”) light sources, a driver circuit that drives the array of LED light sources, and a controller. Controlling the light fixture includes receiving a first output color spectrum for the array of LED light sources that corresponds to a fixture color output spectrum, performing an optical modification of the fixture output color spectrum, determining, based on the optical modification, a compensation value to modify the first output color spectrum to a second output color spectrum that compensates for changes to the fixture output color spectrum resulting from the optical modification, generating, based on the compensation value, a first control signal to drive the array of LED light sources at the second output color spectrum, and controlling the driver circuit using the first control signal.

Abstract: An orbicular valvular conduit which has no moving parts and is configured to facilitate unidirectional flow of a primary fluid stream by utilizing a counterflowing diverted fluid stream to counteract any opposing fluid stream which flows in the direction opposite the primary fluid stream may include at least one conduit subunit. Each conduit subunit may include a fluid diverging section. A fluid converging section may extend from the fluid diverging section. A valve core may be disposed in the fluid diverging section and the fluid converging section. A primary flow passage may extend through the valve core to accommodate a primary fluid stream. A secondary core passage may be formed by and between the valve core and the fluid diverging section and the fluid converging section.

Abstract: A method of surveying a venue includes scanning at least a portion of the venue using an unmanned aerial vehicle having at least one scanner, converting scan data gathered by the at least one scanner into three-dimensional location data, displaying the three-dimensional location data as a three-dimensional model, analyzing the three-dimensional model, and designating portions of the three-dimensional model with semantic mapping.

Abstract: A method of surveying a venue includes scanning at least a portion of the venue using an unmanned aerial vehicle having at least one scanner, converting scan data gathered by the at least one scanner into three-dimensional location data, displaying the three-dimensional location data as a three-dimensional model, analyzing the three-dimensional model, and designating portions of the three-dimensional model with semantic mapping.

Abstract: Thermochemical energy storage (TCES) for concentrating solar power (CSP) systems provides higher energy density than sensible energy storage systems. An ammonia-based TCES system dissociates endothermically into hydrogen and nitrogen. The stored energy is released when supercritical hydrogen and nitrogen react exothermically to synthesize ammonia. Prior ammonia synthesis systems are unable to produce temperatures consistent with modern power blocks requiring a working fluid, for example steam or carbon dioxide, to be heated to greater than 600° C., for example about 650° C. An ammonia synthesis system heats steam from, for example 350° C. to 650° C. under pressure of about 26 MPa. The hydrogen and nitrogen are preheated with a flow of supercritical fluid prior to the synthesis step to provide reaction rates sufficient to heat power block working fluid to the desired temperature.

Abstract: A method of controlling a plurality of light fixtures. The method includes determining first light outputs for each of the plurality of light fixtures. The method also includes determining a first spectrum of light reflected off of a surface. The method further includes determining a first difference between the first light outputs and desired light outputs for each of the plurality of light fixtures. The method also includes determining a second difference between the first spectrum of light reflected off of the surface and a desired spectrum of light reflected off of the surface. The method further includes calculating an updated output spectrum for the plurality of light fixtures based at least in part on the first difference and the second difference. The method also includes determining a second set of light source output values based at least in part on the updated output spectrum.